High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma

Author:

Delfau-Larue Marie-Hélène123ORCID,Klapper Wolfram4,Berger Françoise5,Jardin Fabrice6,Briere Josette7,Salles Gilles8,Casasnovas Olivier9,Feugier Pierre10,Haioun Corinne311,Ribrag Vincent12,Thieblemont Catherine13,Unterhalt Michael14,Dreyling Martin14,Macintyre Elizabeth15,Pott Christiane16,Hermine Olivier17,Hoster Eva1418

Affiliation:

1. Department of Biological Hematology and Immunology, Assistance Publique Hôpitaux de Paris (AP-HP), Groupe Hospitalier Mondor, Créteil, France;

2. Institut Mondor de Recherche Biomédicale–INSERM U955, Equipe 9, Henri Mondor Hospital, Créteil, France;

3. Université Paris-Est, Créteil, France;

4. Departments of Pathology, Hematopathology Section and Lymph Node Registry, University Hospital Schleswig-Holstein, Kiel, Germany;

5. Department of Pathology, Hospices Civils de Lyon, Lyon-1 University, Pierre Benite, France;

6. INSERM U918, Institute for Research and Innovation in Biomedicine, Centre Henri Becquerel, Rouen, France;

7. Department of Pathology, Hôpital Saint-Louis, AP-HP, Paris, France;

8. Hospices Civils de Lyon, Lyon-1 University, Centre National de la Recherche Scientifique (CNRS), Unite Mixte de Recherche (UMR) 5239, Pierre Benite, France;

9. CHU de Dijon, Dijon, France;

10. Centre Hospitalo-Universitaire Brabois, Nancy, France;

11. Lymphoid Malignancies Unit, GH Mondor, AP-HP, Creteil, France;

12. Institut de Cancérologie Gustave Roussy, Villejuif, France;

13. Department of Clinical Hematology, Hôpital Saint-Louis, AP-HP, Paris, France;

14. Department of Internal Medicine III, University Hospital Munich, Munich, Germany;

15. Biological Hematology, Necker Hospital, Paris Descartes, AP-HP, INSERM 1151, Institut Necker Enfants Malades, Paris, France;

16. Second Medical Department, University Hospital Schleswig-Holstein, Kiel, Germany;

17. Department of Clinical Hematology, University Paris Descartes, CNRS, UMR 8147, Necker Hospital, Paris, France; and

18. Department of Medical Informatics, Biometry, and Epidemiology, University of Munich, Munich, Germany

Abstract

Key Points CDKN2A and TP53 deletions remain of bad prognostic value in younger MCL patients treated according to the current standard of care. CDKN2A and TP53 deletions have independent deleterious effects and should be considered for treatment decisions in addition to MIPI and Ki-67 index.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Reference49 articles.

1. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.;Harris;Blood,1994

2. The Non-Hodgkin’s Lymphoma Classification Project.;A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma;Blood,1997

3. Outcome of deferred initial therapy in mantle-cell lymphoma.;Martin;J Clin Oncol,2009

4. Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management.;Vose;Am J Hematol,2012

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3